← Retour au Screener

Sector: Santé
Open in Terminal → WATLive chart · Key metrics · News · Smart money

Waters Corporation

WAT Large Cap

Healthcare · Diagnostics & Research

Mis à jour: Jun 18, 2026, 22:21 UTC

309,86 €
-0.44% aujourd'hui
52W: 239,78 € – 361,04 €
52W Low: 239,78 € Position: 57.8% 52W High: 361,04 €

Price Chart

Indicateurs clés

P/E Ratio
45.22x
Cours/Bénéfice
Forward P/E
21.6x
P/E prévisionnel
P/S Ratio
9.26x
Cours/Ventes
EV/EBITDA
35.72x
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
30,4 Md €
Capitalisation boursière
Croissance du CA
91.4%
Croissance du CA sur un an
Marge bénéficiaire
11.93%
Marge nette
ROE
5.21%
Rentabilité des capitaux propres
Beta
1.2
Sensibilité au marché
Positions vendeuses
4.56%
% du flottant vendu à découvert
Volume moyen
1,023,103
Volume quotidien moyen

Valuation Analysis

Signal
Overvalued
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Acheter
22 analysts
Avg. Price Target
348,94 €
+12.61% upside
Target Range
300,76 € – 401,01 €

About the Company

Sector: Healthcare Industry: Diagnostics & Research Country: United States Employees: 16,000 Exchange: NYQ

Waters Corporation en bref

Waters Corporation (WAT) is currently trading at 309,86 € with a market capitalization of 30,4 Md €. The trailing P/E ratio stands at 45.22x, with a forward P/E of 21.6x. The 52-week range spans from 239,78 € to 361,04 €; the current price is 14.2% below the yearly high. Year-over-year revenue growth stands at +91.4%. The net profit margin stands at 11.93%.

💰 Dividende

Waters Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

22 analystes évaluent Waters Corporation (WAT) au consensus : Acheter. L'objectif de cours moyen est de 348,94 €, soit un potentiel de +12.61% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 300,76 € à 401,01 €.

Waters Corporation : la thèse d'investissement en détail

Waters Corporation (WAT) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 91.4% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind.

Le scénario baissier

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 35.72x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

  • The forward P/E of 21.6x is meaningfully below the trailing 45.22x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Points forts
  • Forte croissance du CA de 91.4% sur un an
  • Marge brute élevée de 55.15% — signe d'un pouvoir de fixation des prix
  • Consensus des analystes : Buy
  • Bilan solide avec faible endettement (D/E 36.63)
Points faibles
  • Actuellement jugée surévaluée
  • Free cash flow négatif

Aperçu technique

MM 50 jours
296,37 €
+4.55% vs. cours
MM 200 jours
300,34 €
+3.17% vs. cours
Sous le plus haut 52s
−14.2%
361,04 €
Au-dessus du plus bas 52s
+29.2%
239,78 €

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

Risque de marché (Bêta)
1.2 · Proche du marché
Évolue plus que le marché global
Positions vendeuses
4.56% · Faible
% du flottant vendu à découvert
Dette/Capitaux propres
36.63 · Faible
Dette totale / capitaux propres

The data points to market-like volatility.

Trading Data

50-Day MA: 296,37 €
200-Day MA: 300,34 €
Volume: 685,374
Avg. Volume: 1,023,103
Short Ratio: 3.66
P/B Ratio: 2.28x
Debt/Equity: 36.63x
Free Cash Flow: -437 948 625 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Waters Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut